© 2020 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.
A 24-week, interferon-free regimen pairing two drugs from Bristol-Myers Squibb--60 milligrams (mg) of daclatasvir, a once-daily NS5a...
A 12-week, interferon-free combination of two experimental, once-daily drugs--ABT-450/r, a Norvir (ritonavir)-boosted hepatitis C protease inh...
A 12-week regimen of ribavirin plus two experimental drugs from Abbott Laboratories--ABT-450, a once-daily hepatitis C protease inhibitor boos...
Early follow-up data from small evaluations of Gilead Sciences’ nucleotide analog GS-7977 plus ribavirin in people with genotype 1 hepa...
All-oral treatment with 24 weeks of daclatasvir, Bristol-Myers Squibb’s once-daily NS5a inhibitor, and GS-7977, Gilead’s once-daily...
A novel version of interferon, pegylated interferon lambda-1a (peg-IFN-lambda), combined with ribavirin cured up to three-quarters of...
Ninety percent of people with genotype 1 hepatitis C virus (HCV) starting therapy for the first time show a clear sign of being cured of their...
Up to 80 percent of people with genotype 1 hepatitis C virus (HCV) who didn’t respond successfully to earlier therapy were cured of their infe...
Additional data from a Merck-sponsored clinical trial help clarify the efficacy of Victrelis (boceprevir) combined with pegylated interferon a...
You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.
Click here to log back in.
